AGP Executive Report
Last update: 9 hours agoGLP-1 Muscle Safety: Regeneron reported Phase 2 results that its experimental antibody trevogrumab, added to semaglutide, cut lean-mass loss by about 42% over one year—an issue that matters for older adults using Wegovy/Ozempic-like drugs. Medication Side Effects: New studies suggest people on GLP-1s may be more likely to report hair loss and nail changes, though the findings don’t prove the drugs directly cause them. Cancer Treatment Complication: A new study on acute promyelocytic leukemia links the number of red-blood-cell transfusions to risk of differentiation syndrome, a serious complication during ATRA/ATO therapy. Food Safety Alert (Italy-relevant): A frozen pasta sold at Walmart was recalled over possible Listeria contamination; the risk is highest for pregnant people, elderly, and immunocompromised. Public Health Policy: The Vatican’s top diplomat reiterated universal health care as a “moral imperative” at the UN. Local Health Leadership: Dr. Tufail Ahad Baba was elected to a Milan-based infectious disease board for 2027–2030.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
